Salmon Calcitonin

• Indication: Osteoporosis

  • Suppresses excess bone resorption

• Novartis has completed 277 subject Phase IIa study, achieving statistically significant results

  • Phase IIb studies scheduled to begin early next year

• Indication: Osteoarthritis

  • Suppresses cartilage degradation
  • Provides pain relief
  • Phase III studies scheduled to begin next year

Previous slide

Next slide

Back to first slide

View graphic version